Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content
Fig. 10 | Biomarker Research

Fig. 10

From: S100A9 as a potential novel target for experimental autoimmune cystitis and interstitial cystitis/bladder pain syndrome

Fig. 10

Paquinimod inhibition and S100A9 knockdown significantly improved bladder function in EAC mice (n = 6). (A) Analysis of cystometry data from control, EAC and paquinimod treatment groups. (B) Comparative analysis of micturition frequency (MF), maximum bladder pressure (MBP) and inter-contraction interval (ICI) in the control, EAC and paquinimod treatment groups. (C) Analysis of cystometry data of WT, S100A9−/−, EAC and S100A9−/− +EAC groups. (D) Comparative analysis of MF, MP and ICI in the WT, S100A9−/−, EAC and paquinimod treatment groups. NS indicates no difference; *p < 0.05, **p < 0.01, ***p < 0.001

Back to article page

Biomarker Research

ISSN: 2050-7771

Contact us